(Reuters) – Novavax Inc has signed an agreement with Endo International for manufacturing its experimental COVID-19 vaccine, the generic drugmaker said on Friday.
Endo said its unit Par Sterile has begun production of the final drug product, with initial batches to be used in Novavax’s phase-3 clinical trial in the United States.
(Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)
